Literature DB >> 22230732

Tumor associated antigen specific T-cell populations identified in ex vivo expanded TIL cultures.

Niels Junker1, Pia Kvistborg, Tania Køllgaard, Per thor Straten, Mads Hald Andersen, Inge Marie Svane.   

Abstract

Ex vivo expanded tumor infiltrating lymphocytes (TILs) from malignant melanoma (MM) and head & neck squamous cell carcinoma (HNSCC) share a similar oligoclonal composition of T effector memory cells, with HLA class I restricted lysis of tumor cell lines. In this study we show that ex vivo expanded TILs from MM and HNSCC demonstrate a heterogeneous composition in frequency and magnitude of tumor associated antigen specific populations by Elispot IFNγ quantitation. TILs from MM and HNSCC shared reactivity towards NY ESO-1, cyclin B1 and Bcl-x derived peptides. Additionally we show that dominating T-cell clones and functionality persists through out expansion among an oligoclonal composition of T-cells. Our findings mirror prior results on the oligoclonal composition of TIL cultures, further indicating a potential for a broader repertoire of specific effector cells recognizing the heterogeneous tumors upon adoptive transfer; increasing the probability of tumor control by minimizing immune evasion by tumor cell escape variants.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22230732     DOI: 10.1016/j.cellimm.2011.12.004

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  12 in total

1.  Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma.

Authors:  J Bae; T Hideshima; G L Zhang; J Zhou; D B Keskin; N C Munshi; K C Anderson
Journal:  Leukemia       Date:  2017-11-01       Impact factor: 11.528

2.  [Immunotherapy of head and neck cancer. Current developments].

Authors:  P J Schuler; T K Hoffmann; T C Gauler; C Bergmann; S Brandau; S Lang
Journal:  HNO       Date:  2013-07       Impact factor: 1.284

3.  CAR-T cells and combination therapies: What's next in the immunotherapy revolution?

Authors:  Maria C Ramello; Eric B Haura; Daniel Abate-Daga
Journal:  Pharmacol Res       Date:  2017-12-01       Impact factor: 7.658

Review 4.  The past, present and future of immunotherapy against tumor.

Authors:  Tao Jiang; Caicun Zhou
Journal:  Transl Lung Cancer Res       Date:  2015-06

5.  The microenvironment of human neuroblastoma supports the activation of tumor-associated T lymphocytes.

Authors:  Lena-Maria Carlson; Anna De Geer; Baldur Sveinbjørnsson; Abiel Orrego; Tommy Martinsson; Per Kogner; Jelena Levitskaya
Journal:  Oncoimmunology       Date:  2013-03-01       Impact factor: 8.110

6.  Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients.

Authors:  Eva Ellebaek; Trine Zeeberg Iversen; Niels Junker; Marco Donia; Lotte Engell-Noerregaard; Özcan Met; Lisbet Rosenkrantz Hölmich; Rikke Sick Andersen; Sine Reker Hadrup; Mads Hald Andersen; Per thor Straten; Inge Marie Svane
Journal:  J Transl Med       Date:  2012-08-21       Impact factor: 5.531

7.  BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer.

Authors:  Marco Donia; Paolo Fagone; Ferdinando Nicoletti; Rikke Sick Andersen; Estrid Høgdall; Per Thor Straten; Mads Hald Andersen; Inge Marie Svane
Journal:  Oncoimmunology       Date:  2012-12-01       Impact factor: 8.110

Review 8.  The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunities.

Authors:  Monika E Freiser; Paolo Serafini; Donald T Weed
Journal:  Immunol Res       Date:  2013-12       Impact factor: 4.505

9.  A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients.

Authors:  J Bae; R Prabhala; A Voskertchian; A Brown; C Maguire; P Richardson; G Dranoff; K C Anderson; N C Munshi
Journal:  Leukemia       Date:  2014-05-14       Impact factor: 11.528

Review 10.  T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities.

Authors:  Zhan Wang; Binghao Li; Yingqing Ren; Zhaoming Ye
Journal:  Front Immunol       Date:  2016-09-14       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.